GLP-1 Costs & the Shift to Metabolic Optimization in Benefits | 2026
GLP-1 Costs & the Shift to Metabolic Optimization in Benefits | 2026 Something shifted in benefits meetings over the past two years — and it happened faster than most people in the room expected. The conversation used to be fairly predictable: diabetes management spend, cardiovascular disease claims, the annual debate about whether the wellness program was actually doing anything. Familiar territory, if not exactly comfortable. Then GLP-1 medications arrived in force. And the entire vocabulary of the room changed. Not just the drugs themselves — though those are reshaping budgets in ways that benefits managers are still scrambling to model accurately — but the language surrounding them. "Metabolic optimization." "Cardiometabolic risk stratification." "Upstream intervention." These phrases are no longer confined to clinical research papers. They're in the pitch decks, in the benefit design discussions, in the questions HR directors are ask...